125 µg and 250 µg

  • Fluticasone propionate given by inhalation offers preventative treatment for asthma. At recommended doses it has a potent glucocorticoid anti-inflammatory action within the lungs, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.
  • Prophylactic management of asthma.
  • Symptomatic treatment of chronic obstructive pulmonary disease (COPD).
  • Clinical Studies : Pharmacokinetic studies and phase III study.
  • Our product has been developed as capsules containing dry powder for inhalation at a fluticasone dosage of 125 µg and 250 µg in HPMC capsules to be used in the Axahaler® DPI device. Laboratoires SMB’s product has enhanced bioavailability where the same efficacy has been proven clinically with half the dose of the reference product.
  • Publications : Izabela Kupryś-Lipińska, Damian Tworek, Francis Vanderbist, Małgorzata Bocheńska-Marciniak, Piotr Kuna. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma. Pneumonol Alergol Pol 2013 ;81(6):527-36.
logo blanc